Please assess the completion status of the following clinical trial:

Trial Title: The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria:~1. male gender~2. age 73 or younger~3. presence of CHD~4. HDL-C le 40 mg/dl~5. LDL-C le 140 mg/dl~6. triglycerides le 300 mg/dl~Exclusion Criteria:~Exclusion criteria:~1. significant medical illness~2. alcohol or substance abuse~3. evidence of cholecystitis or cholelithiasis~4. ejection fraction of lt 35%~5. current use of steroids, estrogens, immunosuppressive agents, oral coagulants, or lipid modifying drug.~6. allergic to gemfibrozil or fibric acid~7. refused informed consent

- Gender: MALE
- Minimum Age: None
- Maximum Age: 73 Years
- Healthy Volunteers: f

Study Arms:
- Gemfibrozil (Type: ACTIVE_COMPARATOR): 1200 mg slow-release gemfibrozil (Lopid-SR) once per day
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablets taken once per day

Based on this trial design, predict the completion outcome and termination type (if applicable).